RxDoctor Payments Data

Susan Phelan, NP

Nurse Practitioner · Port Jefferson, NYNPI 1487711636

Payments from drug & device makers

$2,020in general payments, 2019–2025

Across 85 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$598
  • Vanda Pharmaceuticals Inc.$289
  • Lundbeck LLC$244
  • Teva Pharmaceuticals USA, Inc.$179
  • Johnson & Johnson$116
  • Takeda Pharmaceuticals U.S.A., Inc.$106
  • plus $487 from 13 others

What the payments were for

  • Food & beverage$2,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,020 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$25,279
Medicare patients
15
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Wellbutrin XlBupropion Hcl24$54,126
XanaxAlprazolam12$7,613
Ambien CrZolpidem Tartrate12$7,536
CymbaltaDuloxetine Hcl24$6,546
VyvanseLisdexamfetamine Dimesylate12$5,310
Alprazolam21$602
Buspirone Hcl28$548
Methylphenidate Hcl29$534
Aripiprazole16$483
Bupropion XlBupropion Hcl34$426
Oxcarbazepine24$410
Alprazolam ErAlprazolam19$384
Lorazepam25$296
Trazodone Hcl30$292
Gabapentin40$276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$106$5,31012 claims
Almatica Pharma LLCSertraline Hcl$50$12320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Port Jefferson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →